Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Neuropathol Appl Neurobiol. 2013 Apr;39(3):270–283. doi: 10.1111/j.1365-2990.2012.01279.x

Figure 3. MBP-induced CCL2 and IL-6 are mediated, in part, by the p38 MAPK pathway.

Figure 3

(A) CCL2 and (B) IL-6 proteins were determined as percent difference compared to MBP (set to 100%). EC were pretreated with 10μM of the MEK1/2 MAPK inhibitor, U0126, 10μM of the p38 MAPK inhibitor, SB203580, or 10μM of the phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 for 1 hour, then treated with or without 100μg/ml MBP for an additional 24 hours Shown are the means of 4 (CCL2) and 3 (IL-6) separate experiments ±SEM. *p<0.003, #p<0.04 compared to untreated; and **p<0.005 compared to MBP. U0=U0126 at 10μM, LY=LY294002 at 10μM, SB=SB203580 at 10μM.